Colorectal Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older.
- People who have been diagnosed with rectal cancer (a specific type called rectal adenocarcinoma), confirmed by tissue testing, for which a combination of chemotherapy and radiation therapy before surgery has been recommended.
- People whose general health and ability to carry out daily activities meets a certain minimum level, as measured by standard health scoring tools (confirm with trial site).
- People who have given signed agreement to take part in the trial.
- Women who could become pregnant must agree to use effective contraception throughout the treatment period.
- People who are covered by, or entitled to benefit from, a social security scheme (this criterion relates to the French healthcare system — confirm with trial site).
Who may not be able to join:
- People whose rectal cancer has a predominantly mucus-producing nature, as seen on scans, biopsy, or tissue analysis, as this can affect the accuracy of certain scan measurements used in the trial.
- People who cannot have an MRI scan — for example, those with a pacemaker that is not MRI-compatible, certain metal implants in the body, or severe claustrophobia.
- People who are receiving radiation therapy only, without chemotherapy.
- People receiving any other type of pre-surgery treatment alongside what the trial specifies.
- People whose surgery is expected to be delayed more than approximately 10 weeks after finishing the pre-surgery treatment, or where surgery has been cancelled.
- People with severe liver problems or severely reduced kidney function, as these conditions make the chemotherapy drug used in this trial (capecitabine) unsuitable.
- People with a known deficiency of a specific enzyme (DPD) that processes certain chemotherapy drugs, or those with a known allergic reaction to the chemotherapy drugs used in this trial (5-FU or capecitabine) or their ingredients.
- People currently taking part in another clinical trial that involves receiving another treatment at the same time.
- People who are pregnant, likely to become pregnant without using effective contraception, or who are breastfeeding.
- People in emergency situations, people who are under a legal protection order, or people who are unable to give their own consent to participate.
- People who would be unable to attend the required medical appointments for geographical, social, or psychological reasons.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Marguerite TYRAN, MD, Institut Paoli-Calmettes
Phone: 33491223778
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Predictive value of Apparent Diffusion Coefficient measured using MRgRT system
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.